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Abstract: Herb-induced liver injury (HILI) has recently attracted attention due to increasing reports
of hepatotoxicity associated with use of phytotherapeutics. Here, we present data on HILI from the
Berlin Case-Control Surveillance Study. The study was initiated in 2000 to investigate the serious
toxicity of drugs including herbal medicines. Potential cases of liver injury were ascertained in more
than 180 Departments of all 51 Berlin hospitals from October 2002 to December 2011. Drug or herb
intake was assessed through a standardized face-to-face interview. Drug or herbal aetiology was
assessed based on the updated Council for International Organizations of Medical Sciences scale. In
ten of all 198 cases of hepatotoxicity included in the study, herbal aetiology was assessed as probable
(once ayurvedic herb) or possible (Valeriana five times, Mentha piperita once, Pelargonium sidoides
once, Hypericum perforatum once, Eucalyptus globulus once). Mean age was 56.4 ˘ 9.7 years, and the
predominant pattern of liver injury was hepatocellular. No cases of acute liver failure or death were
observed. This case series corroborates known risks for ayurvedic herbs, supports the suspected
association between Valeriana use and liver injury, and indicates a hepatotoxic potential for herbs
such as Pelargonium sidoides, Hypericum perforatum or Mentha piperita that were rarely associated with
liver injury before. However, given that possible causality does not prove clinical significance, further
studies in this field are needed.
Keywords: hepatotoxicity; phytotherapeutics; pharmacovigilance
1. Introduction
Intake of herbs has increased over the last years, although data proving efficacy are lacking for
most compounds [1]. Several factors may account for this development, including the belief that
herbs are safe because they are “natural”, and that they depict a harmless alternative to conventional
medicine. Moreover, as they are predominantly non-prescription drugs, they can be easily obtained
in drug stores, health stores or via the internet [1]. According to recent data, increased herbal
consumption has been accompanied by an increase in cases of herb-induced liver injury (HILI) [2–4].
Until today, many different compounds have been linked to liver damage, and for some of them, a
high hepatotoxic potential is assumed [5]. However, herbal intake is common even amongst people
with existing hepatobiliary disorders [1], probably reflecting the aforementioned attitudes towards
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herbs in the general population, and the fact that physicians are often unaware of their patients’ use
of phytotherapeutics.
Symptoms of HILI can range from mild asymptomatic liver enzyme elevation to more severe
conditions such as cirrhosis or acute liver failure (ALF) [5]. A recent prospective cohort study
using data from the US Drug-Induced Liver Injury Network (DILIN) showed that hepatic damage
from non-bodybuilding herbs and dietary supplements led more often to liver transplantation than
conventional drugs (13% vs. 3%) [3]. Another US study showed that two-thirds of emergency
department visits for single-supplement-related adverse events involved herbal or complementary
nutritional products [6]. These findings highlight the significance of HILI and the need to acquire more
data on potentially hepatotoxic herbs and characteristics of the respective patients.
Previously, we reported the results of the case-control analysis on drug-induced liver injury from
the Berlin Case-Control Surveillance Study FAKOS (Fall-Kontroll-Studie) [7]. The present study aims
to contribute further information on the field of HILI. We present a descriptive overview of patients
with HILI from the FAKOS study including demographic, clinical, laboratory, and histological features.
Moreover, literature on the hepatotoxic potential of the herbs involved is reviewed.
2. Results
2.1. Case Series
Of the 198 patients overall with hepatotoxicity initially included into the FAKOS study, ten
patients (5.1%) showed a possible or probable herbal aetiology. In seven of these patients, the
hepatotoxic reaction occurred in the ambulatory setting requiring hospitalisation, and in the other
three patients, it occurred during the hospital stay. Table 1 illustrates demographic, clinical, and
laboratory characteristics. Seven patients were female, three patients were male, mean age was
56.4˘ 9.7 years, and the predominant pattern of liver injury according to the ratio R was hepatocellular.
Mean alanine aminotransferase (ALT)/upper limit of normal (ULN) ratio was 19.2, mean aspartate
aminotransferase (AST)/ULN ratio was 14.3, and mean alkaline phosphatase (ALP)/ULN ratio was
2.3. Five patients depicted hyperbilirubinaemia and coagulopathy was identified in two patients.
All serologic tests conducted for viral hepatitis were negative. The most common symptoms were
fatigue (seven patients) and jaundice (four patients). No cases of hepatic encephalopathy or ALF
were observed, and none of the patients died. Table 2 summarizes the histologic features of the six
patients with available liver biopsy results. Five patients showed signs of necrosis either disseminated
or predominantly near the central vein (zone III). Portal inflammation was slightly more common
than lobular inflammation, and the infiltrates contained mostly lymphocytes, neutrophil or eosinophil
granulocytes. Canalicular cholestasis was seen in one patient. Tables 3 and 4 show the findings based
on the updated Council for International Organizations of Medical Sciences (CIOMS) scale: in one
case the association between herb intake and hepatotoxicity was assessed as probable (ayurvedic
herb) and in nine cases the association was assessed as possible (five times Valeriana, once Mentha
piperita, Pelargonium sidoides, Hypericum perforatum, and Eucalyptus globulus, respectively). Known lead
substances of the assessed phytotherapeutics are illustrated in Figure 1. In nine cases, drugs apart
from herbs were also suspected as potentially hepatotoxic (Tables 3 and 4). Regarding the time course
of liver enzymes, drug or herb cessation always led to a significant enzymatic decrease.
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Table 1. Selected demographic, clinical, and laboratory data of the patients with herb-induced liver injury.
1 2 3 4 5 6 7 8 9 10






globulus Valeriana Valeriana Valeriana
Sex Female Female Female Female Male Female Male Male Female Female
Age (years) 60 65 57 70 46 52 50 46 71 47




ALT/ULN 34.9 19.2 7.5 3.5 73.6 34.7 6.1 3.5 4.1 4.6
AST/ULN 49.2 12.8 4.7 4.6 44.6 15.2 3.1 3.3 3.4 2.5
ALP/ULN 1.0 5.2 5.8 0.6 2.0 1.6 0.4 0.8 3.1 Missing
Bilirubin total (mg/dL) 35.3 2.0 7.1 7.8 3.8 1.0 0.5 0.5 0.5 Missing
Coagulopathy 2 Yes (INR: 1.6) No No Yes (INR: 1.9) No No No No No No
Serology testing
Hepatitis A virus Negative Negative Negative Negative Negative Negative Missing Negative Negative Negative
Hepatitis B virus Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
Hepatitis C virus Negative Negative Negative Negative Negative Negative Negative Negative Missing Negative
Cytomegalovirus Negative Negative Missing Missing Missing Missing Negative Missing Missing Missing
Epstein-Barr virus Negative Negative Missing Missing Missing Missing Negative Missing Missing Missing
Hepatitis E virus Negative Missing Missing Missing Missing Missing Missing Missing Missing Missing
Herpes simplex virus Negative Missing Missing Missing Missing Missing Negative Missing Missing Missing
Varicella zoster virus Negative Missing Missing Missing Missing Missing Negative Missing Missing Missing
Autoimmune antibodies
testing ANA 1:320 Negative ANA 1:160 Negative Negative Negative Missing Negative Negative Missing
Abdominal sonography Conducted Conducted Conducted Conducted Conducted Conducted Conducted Conducted Conducted Conducted
Symptoms
Fatigue Yes Yes Yes Yes Yes Yes No Yes No No
Jaundice Yes No Yes Yes Yes No No No No No
Acholic faeces/dark urine Yes No Yes No Yes No No No No No
Abdominal pain No Yes Yes No No No No No No No
Signs of hypersensitivity 3 Yes No No No Yes No No No No No
Hepatic encephalopathy No No No No No No No No No No
Acute liver failure 4 No No No No No No No No No No
Death No No No No No No No No No No
1 As ALP remained normal, the pattern of liver injury was classified as hepatocellular although the ratio ALT/ULN/ALP/ULN was lower than 5 (4.4); 2 INR > 1.2; 3 Fever, rash,
lymphadenopathy, arthralgia, myalgia and/or eosinophilia; 4 Severe coagulopathy (INR > 1.5) and hepatic encephalopathy. ALT = alanine aminotransferase; ULN = upper limit of
normal; AST = aspartate aminotransferase; ALP = alkaline phosphatase; ANA = antinuclear antibodies; INR = International Normalized Ratio.
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Table 2. Histologic features of the patients with herb-induced liver injury.
Histologic Features 1 2 3 4 8 9
Suspected herb Ayurvedic herb Hypericum perforatum Valeriana Valeriana Valeriana Valeriana
Necrosis +++ + + + + ´
Necrosis localisation Zone III Disseminated Disseminated Zone III Disseminated Not applicable
Lobular inflammation + + + + + ´
Portal inflammation ++ ++ ++ + ´ +
Plasma cells ++ ´ + ? ´ ´
Eosinophils + + ´ ? + ´
Neutrophils ++ ´ + ? + ´
Lymphocytes ´ ++ ++ ? ´ +
Canalicular cholestasis ´ ´ ++ ´ ´ ´
? = no data available.
Table 3. Data on drug or herb intake of the patients with herb-induced liver injury and hepatocellular patterns.
1 4 5 6 7 8 10 1
Causality assessment 2
probable Ayurvedic herb 3 (6) - ASA/Vitamin C (6) - Clarithromycin (6) - -
possible
Metoprolol (4) Metformin (5) Mentha piperita (3) PS (4) Eucalyptus globulus (3) Venlafaxine (4) Valeriana (4)
- Paroxetine (5) - - Multivitamins (3) Valeriana (3) Citalopram (3)
- Valeriana (4) - - - - -
- Multivitamins (3) - - - - -
Time to onset from the beginning of drug/herb
5–90 days Ayurvedic herb - - - All - All
<5 or >90 days Metoprolol All All - - Valeriana -
OR: Time to onset from cessation of drug/herbď15 days
(except for slowly metabolized chemicals: >15 days) - - - PS - Venlafaxine -
Course of ALT after cessation of the drug/herb
(percentage difference between ALT peak and N) - - - - - - -
Decreaseě50% within 8 days - - All - All - -
Decreaseě50% within 30 days - All - - - All All
No information All - - PS - - -
Decreaseě50% after the 30th day
Decrease <50% after the 30th day or recurrent increase - - - - - - -
ALT normalization after cessation of drug/herb Not known Not known Not known Not known Yes (30 days) Yes (10 days) Not known
1 The pattern of liver injury could not be assessed as no ALP values were available and no liver biopsy was conducted; 2 Based on the updated CIOMS score as proposed by
Teschke et al. [4]; 3 Tea containing liquorice, ginger, cardamom, and cinnamon. Herbs are written in bold. Numbers in brackets depict the points in CIOMS score for each compound.
ASA = acetyl salicylic acid; PS = Pelargonium sidoides; ALT = alanine aminotransferase; N = enzyme value at a certain time point; CIOMS = Council for International Organizations of
Medical Sciences.
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Table 4. Data on drug or herb intake of the patients with herbal-induced liver injury and cholestatic or mixed patterns.
2 3 9
Causality assessment 1 - - -
probable - - -
possible
Hypericum perforatum (5) Carbimazole (5) Enoxaparin (4)
Promethazine (5) Phenprocoumon (5) Metamizole (3)
- Valeriana (3) Valeriana (3)
Time to onset from the beginning of drug/herb
5–90 days Hypericum perforatum Carbimazole,Phenprocoumon All
<5 or >90 days Promethazine Valeriana -
OR: Time to onset from cessation of drug/herb ď15 days (except for slowly metabolised chemicals: >15 days)
Course of ALP after cessation of the drug/herb (percentage difference between ALP peak and N) - - -
Decrease ě50% within 180 days All - -
Decrease <50% within 180 days - All All
No information, persistence, increase, or continued drug/herb use - - -
ALP normalisation after cessation of the drug/herb Not known Not known Not known
1 Based on the updated CIOMS score as proposed by Teschke et al. [4]. Herbs are written in bold. Numbers in brackets depict the points in CIOMS score for each compound.
ALP = alkaline phosphatase; N = enzyme value at a certain time point; CIOMS = Council for International Organizations of Medical Sciences.
Figure 1. Chemical structures of lead substances of assessed phytotherapeutics.
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2.2. A Case with Probable Herbal Causality
Patient 1 used an ayurvedic tea containing liquorice, ginger, cardamom, and cinnamon several
times. Within two weeks, she developed jaundice, fatigue, abdominal pain, and an exanthema and
was hospitalised. Except for the aforementioned herb, the patient received metoprolol 50 mg daily
for the past 14 years due to arterial hypertension with no complications. Laboratory analysis showed
strongly increased transaminases and bilirubin, coagulopathy, as well as slightly increased antinuclear
antibodies (Table 1). Liver biopsy was compatible with the enzymatic pattern of hepatic damage
revealing hepatocellular necrosis as the main characteristic (Table 2). Viral or biliary aetiologies were
excluded, alcohol intake was denied. The herb and the beta blocker were stopped and a treatment
with corticosteroids was initiated. The patient showed clinical improvement and a decrease of the
transaminases in the next three weeks (AST: about 80% reduction; ALT: about 20% reduction) and was
thereafter discharged from the hospital. The causality of the metoprolol was classified as “possible”
due to its less indicative time course.
2.3. A Case Associated with the Use of Pelargonium sidoides
Patient 6 received Pelargonium sidoides as drops due to a common cold for five days. A few days
later she developed fatigue, and two weeks after herb cessation, ambulatory control of liver enzymes
showed strongly increased transaminases. In hospital, a limited serologic analysis (including only
hepatitis A virus, hepatitis B virus and hepatitis C virus) did not reveal any signs of viral hepatitis
and abdominal imaging excluded a biliary aetiology (Table 1). Clinical improvement and fast decrease
of both transaminases were followed by patient’s discharge. Although no other medications were
compatible with the time course of the illustrated symptoms, as dechallenge assessment was performed
long after stopping herb use, only a possible aetiology can be attributed to Pelargonium sidoides (Table 3).
3. Discussion
This series provides data from ten well phenotyped hepatotoxicity cases with probable or possible
herbal aetiology. Since, in FAKOS, the overall number of hepatotoxicity cases was 198, liver damage
associated with herbs seems to be rare in our data (circa 5%). The US DILIN study showed that
15.5% of hepatotoxicity cases were associated with herb intake [3], suggesting a greater relevance
for HILI in the US than in Germany where FAKOS was conducted. However, HILI cases in DILIN
cumulated drastically during study period, beginning from 7% of the overall cases in 2004 and
reaching 20% in 2014. As case recruitment in FAKOS spanned from 2002 to 2011, we assume that
not only country-specific but also time-specific factors may account for this difference. The most
common pattern of liver injury in our series was hepatocellular (60%). This is in accordance with
the DILIN publication, in which the respective number was 71% [3]. Sex distribution in cases is also
comparable, as in both studies mainly female patients developed liver damage associated with herb
intake (70% in FAKOS vs. 65% in DILIN). As consumption of phytotherapeutics is generally more
widespread among women [8], the observed female “predominance” regarding HILI could derive
from the higher exposure.
In our case series, the causality of one herb was assessed as probable (ayurvedic herb in patient 1).
Regarding ayurvedic treatment, several reports on hepatotoxicity were published in the last years,
with most of them referring to Centella asiatica, an herb used for various psychiatric, cardiologic
or dermatologic indications [9–11]. Patient 1 received a tea containing several ingredients, making
precise assumptions regarding the hepatotoxic potential of the specific components challenging.
Although metoprolol-induced hepatotoxicity cannot be ruled out (Table 3), this case further supports a
hepatotoxic potential for ayurvedic herbs.
Concerning Pelargonium sidoides, the Drug Commission of the German Medical Association
reported several cases of hepatotoxicity associated with its use in 2011 [12]. However, a re-evaluation
based on the updated CIOMS score revealed no highly probable or probable causalities [13]. In our
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case, the causality was assessed as possible. Other drugs were excluded as possible aetiologies, but
serologic testing was limited and dechallenge was assessed long after herb use cessation. On the
regulatory level, the European Medicines Agency stated in 2013 that “hepatotoxicity and hepatitis
cases were reported in association with administration of Pelargonium sidoides” and that “in case signs
of hepatotoxicity occur, its administration should be stopped immediately and a medical doctor should
be consulted” [14]. Accordingly, the Federal Institute for Drugs and Medical Devices in Germany
imposed respective changes in labelling [15]. Altogether, a hepatotoxic potential of Pelargonium sidoides
cannot be excluded, and considering the low quality of data regarding its efficacy in upper respiratory
tract infections [16], it should be used cautiously.
Liver damage associated with Valeriana has been reported in the past [17–20], although none of the
ingredients of its extracts (e.g., valerenic acid, Figure 1) are known to be specifically hepatotoxic [21].
In our series, all five cases assessed showed a possible causality. The symptoms were mild, the
pattern of liver injury varied, and the enzymatic changes were moderate. In our previously published
case-control study Valeriana showed an increased risk, although statistical significance was scarcely
missed (odds ratio 5.3, 95% confidence interval 0.98–27.3) [7]. Regarding the three other herbs assessed
as potentially hepatotoxic (Hypericum perforatum, Mentha piperita, Eucalyptus globulus), existing literature
is limited. Hypericum perforatum was linked to liver damage in two case reports, with the authors
suggesting drug–drug interactions as a potential triggering mechanism [22,23]. No data exist regarding
the hepatotoxic potential of its two main compounds hyperforin and hypericin (Figure 1). In our
case the hepatotoxic causality remains unclear, as the co-administered promethazine also showed
a possible causality and jaundice is listed as a known adverse event in its Summary of Product
Characteristics [24]. A risk quantification conducted in our case-control study could also not sufficiently
clarify the hepatotoxic potential of Hypericum perforatum due to the low number of exposed cases and
controls (odds ratio 2.9, 95% confidence interval 0.2–35.3) [7]. To our knowledge, no published cases
of liver damage linked to the use of Mentha piperita exist. An in vitro study showing a hepatotoxic
potential for high-dose Mentha piperita proposed a mechanism involving not its main compound
menthol (Figure 1), but pulegone, a monoterpene found in low concentrations in oil extracts which
can cause acute hepatic necrosis in in vivo experimental models [25]. This compound could also be
responsible for the cases of liver injury associated with other members of the same genus such as
Mentha pulegium [26–29] or Mentha haplocalyx Brig [30]. Finally, despite the existence of preclinical
data implicating a hepatotoxic potential for the main compound of Eucalyptus globulus 1,8-cineole
(Figure 1), involving central venous congestion, granular degeneration, vacuolar degeneration and
hepatic necrosis [31,32], there are no cases of liver damage in association with its use.
Some limitations of this study need to be addressed. Firstly, herbs gathered equal or more
points than “conventional” drugs in the updated CIOMS score only in four of the ten reported cases.
Therefore, the possibility of a non-herb drug aetiology cannot be excluded in most patients. Secondly,
since HILI is a diagnosis of exclusion and relatively common hepatitis causes such as infections by
cytomegalovirus, Epstein-Barr virus, hepatitis E virus (HEV), herpes simplex virus or varicella zoster
virus were rarely excluded in our patients, an infectious aetiology cannot be ruled out for every case.
This is particularly important for HEV, since recent publications suggest that although accounting for
some cases of suspected drug-induced liver injury, serologic testing excluding a respective infection is
not regularly performed [33,34]. Finally, case series are not suitable for risk quantification due to the
missing denominator, and definite conclusions regarding clinical characteristics or outcomes cannot be
provided. However, similarly to spontaneous adverse drug reports, they can serve as a tool to produce
risk signals and raise awareness of potential safety problems [35].
Altogether, our data illustrate a further contribution to the field of HILI. They corroborate known
risks for Valeriana and ayurvedic herbs and implicate a hepatotoxic potential for Pelargonium sidoides,
Hypericum perforatum, and other compounds only seldom or never linked to liver damage thus far.
They also demonstrate the challenges regarding causality assessment of HILI cases, particularly when
it comes to the exclusion of alternative diagnoses since respective data are often missing. Therefore,
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further thoroughly conducted epidemiological studies quantifying hepatotoxic risks for various herbs
remain indispensable.
4. Patients and Methods
4.1. Case Identification and Recruitment
The hospital based case-control surveillance study FAKOS was initiated in 2000 in order to
study serious toxicity of drugs including hepatotoxicity [7,36,37]. Potential cases of liver injury
were ascertained in more than 180 Departments of Internal Medicine, Neurology, Psychiatry, and
Anaesthesiology of all 51 Berlin hospitals from October 2002 until December 2011. The physicians
in these departments were contacted regularly in two- to three-week intervals to identify potential
cases, and between these intervals cases were actively reported to the study center. Eligible patients
were contacted by a trained staff member of FAKOS in order to obtain the patients’ written informed
consent. Moreover, a standardized face-to-face interview was conducted, ascertaining information
on all previous intakes of drugs or herbs, on co-morbidities, demographic data, and other possible
risk factors such as chemicals or solvents. Intake of drugs or herbs was also ascertained by reviewing
medical charts. Berlin, with 2.8 million inhabitants as an adult source population, comprised the
study region. The Ethics Committee of the Charité-Universitätsmedizin Berlin approved the study
(Date: 17 July 2000; Case number: 1369/2000).
4.2. Case Definition, Validation and Characterization
Patients with a minimum age of 18 years and a new diagnosis of hepatotoxicity within the last
six months were included in the study. Inclusion laboratory criteria were an elevation of ALT or AST
threefold above ULN or an elevation of total bilirubin higher than 2 mg/dL. Excluded were patients
with underlying liver disease (including, amongst others, acute or chronic infectious hepatitis, alcoholic
fatty liver disease, autoimmune hepatitis, liver tumors or hepatic metastases, extrahepatic bile duct
obstruction, ischaemic hepatitis or congestive hepatopathy). Hepatotoxicity was validated as certain,
probable, possible or unlikely based on information about laboratory, imaging or histological tests
and clinical information including exclusion criteria provided on a standardised form by the treating
physician to the study center. Only patients with certain or probable hepatotoxicity were further
considered. Grading as hepatocellular, cholestatic or mixed type was based on the determination of
the ratio R of the relative rise of ALT to the relative rise of ALP [38]. When ALT or ALP was lacking
and a biopsy had not been conducted, hepatotoxicity was graded as unclassifiable. Coagulopathy
was defined as an International Normalized Ratio (INR) higher than 1.2, hyperbilirubinaemia as
total bilirubin higher than 1.1 mg/dL, and ALF as severe coagulopathy (INR > 1.5) combined with
hepatic encephalopathy.
4.3. Standardized Assessment of Drug or Herbal Causality in Individual Cases
A possible drug or herbal aetiology was assessed for each case by applying the updated CIOMS
scale [39]. Two different CIOMS subscales exist, with the first being for the hepatocellular type of
liver injury and the second for the cholestatic or mixed type. The updated CIOMS scale takes into
account (i) information on the time interval from the beginning of drug or herbal intake until the onset
of symptoms or laboratory abnormalities; (ii) the time course of dechallenge; (iii) the existence of
risk factors such as age ě55 years or high alcohol consumption; (iv) concomitant medications; (v) the
exclusion of alternative causes such as viral hepatitis, hepatobiliary diseases, alcoholism, ischaemia or
complications of underlying diseases; (vi) previous information on hepatotoxicity of the drug or herb;
and (vii) a response to unintentional readministration. According to this scale, drug or herbal causality
can be “highly probable” (score ě 9), “probable” (score 6–8), “possible” (score 3–5), “unlikely” (1–2) or
“excluded” (score ď 0).
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